{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T21:56:09Z","timestamp":1782856569415,"version":"3.54.5"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":47,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Imaging"],"DOI":"10.1186\/s40644-026-01028-6","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T12:07:34Z","timestamp":1775822854000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["[\u00b9\u2078F]PSMA-1007 and [\u00b9\u2078F]FDG PET\/CT in patients with metastatic triple-negative breast cancer: a prospective head-to-head comparison and assessment of PSMA-targeted radioligand therapy applicability"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7835-4939","authenticated-orcid":false,"given":"Tatiana Nikolaevna","family":"Lazutina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8905-4202","authenticated-orcid":false,"given":"Aleksandr Igorevich","family":"Khalimon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4231-5604","authenticated-orcid":false,"given":"Soslan Rolanovich","family":"Urtaev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2172-5778","authenticated-orcid":false,"given":"Malika Maratovna","family":"Khodzhibekova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2920-0328","authenticated-orcid":false,"given":"Daria Yurevna","family":"Khodakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4864-0643","authenticated-orcid":false,"given":"Gulnara Faridovna","family":"Khamadeeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2161-6232","authenticated-orcid":false,"given":"Anastasia Igorevna","family":"Nikiforuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1280-620X","authenticated-orcid":false,"given":"Irina Valentinovna","family":"Pylova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4282-0192","authenticated-orcid":false,"given":"Aleksei Victorovich","family":"Leontev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8784-8415","authenticated-orcid":false,"given":"Andrey Dmitrievich","family":"Kaprin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"1028_CR1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"key":"1028_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-020-01296-5","author":"L Yin","year":"2020","unstructured":"Yin L, Duan JJ, Bian XW, Yu SC. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020. https:\/\/doi.org\/10.1186\/s13058-020-01296-5.","journal-title":"Breast Cancer Res"},{"key":"1028_CR3","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-3045","author":"R Dent","year":"2007","unstructured":"Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-3045.","journal-title":"Clin Cancer Res"},{"key":"1028_CR4","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-1177","author":"AC Garrido-Castro","year":"2019","unstructured":"Garrido-Castro AC, Lin NU, Polyak K. Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment. Cancer Discov. 2019. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-1177.","journal-title":"Cancer Discov"},{"key":"1028_CR5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa180961","author":"P Schmid","year":"2018","unstructured":"Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Di\u00e9ras V, Hegg R, Im SA, Shaw Wright G, Henschel V, Molinero L, Chui SY, Funke R, Husain A, Winer EP, Loi S, Emens LA. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018. https:\/\/doi.org\/10.1056\/NEJMoa180961.","journal-title":"N Engl J Med"},{"issue":"1","key":"1028_CR6","first-page":"81","volume":"3","author":"DA Silver","year":"1997","unstructured":"Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3(1):81\u20135.","journal-title":"Clin Cancer Res"},{"key":"1028_CR7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, Tagawa ST, Nordquist LT, Vaishampayan N, El-Haddad G, Park CH, Beer TM, Armour A, P\u00e9rez-Contreras WJ, DeSilvio M, Kpamegan E, Gericke G, Messmann RA, Morris MJ, Krause BJ. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021. https:\/\/doi.org\/10.1056\/NEJMoa2107322.","journal-title":"N Engl J Med"},{"key":"1028_CR8","doi-asserted-by":"publisher","DOI":"10.1111\/apm.12195","author":"AG Wernicke","year":"2014","unstructured":"Wernicke AG, Varma S, Greenwood EA, Christos PJ, Chao KS, Liu H, Bander NH, Shin SJ. Prostate-specific membrane antigen expression in tumor-associated vasculature of breast cancers. APMIS. 2014. https:\/\/doi.org\/10.1111\/apm.12195.","journal-title":"APMIS"},{"key":"1028_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/s10585-018-9878-x","author":"M Kasoha","year":"2017","unstructured":"Kasoha M, Unger C, Solomayer EF, Bohle RM, Zaharia C, Khreich F, Wagenpfeil S, Juhasz-B\u00f6ss I. Prostate-specific membrane antigen (PSMA) expression in breast cancer and its metastases. Clin Exp Metastasis. 2017. https:\/\/doi.org\/10.1007\/s10585-018-9878-x.","journal-title":"Clin Exp Metastasis"},{"key":"1028_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-018-4717-y","author":"Y Tolkach","year":"2018","unstructured":"Tolkach Y, Gevensleben H, Bundschuh R, Koyun A, Huber D, Kehrer C, Hecking T, Keyver-Paik MD, Kaiser C, Ahmadzadehfar H, Essler M, Kuhn W, Kristiansen G. Prostate-specific membrane antigen in breast cancer: a comprehensive evaluation of expression and a case report of radionuclide therapy. Breast Cancer Res Treat. 2018. https:\/\/doi.org\/10.1007\/s10549-018-4717-y.","journal-title":"Breast Cancer Res Treat"},{"key":"1028_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-016-3563-6","author":"M Sathekge","year":"2017","unstructured":"Sathekge M, Lengana T, Modiselle M, Vorster M, Zeevaart J, Maes A, Ebenhan T, Van de Wiele C. 68Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients. Eur J Nucl Med Mol Imaging. 2017. https:\/\/doi.org\/10.1007\/s00259-016-3563-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"1028_CR12","first-page":"135","volume":"10","author":"S Medina-Ornelas","year":"2020","unstructured":"Medina-Ornelas S, Garc\u00eda-Perez F, Estrada-Lobato E, Ochoa-Carrillo F. 68Ga-PSMA PET\/CT in the evaluation of locally advanced and metastatic breast cancer, a single center experience. Am J Nucl Med Mol Imaging. 2020;10(3):135\u201342.","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"1028_CR13","doi-asserted-by":"publisher","DOI":"10.1097\/MNM.0000000000001663","author":"E Arslan","year":"2023","unstructured":"Arslan E, Erg\u00fcl N, Beyhan E, Erol Fenercioglu \u00d6, Sahin R, Cin M, Battal Havare S, Can Trabulus FD, Mermut \u00d6, Akbas S, Fikret \u00c7ermik T. The roles of 68 Ga-PSMA PET\/CT and 18 F-FDG PET\/CT imaging in patients with triple-negative breast cancer and the association of tissue PSMA and claudin 1, 4, and 7 levels with PET findings. Nucl Med Commun. 2023. https:\/\/doi.org\/10.1097\/MNM.0000000000001663.","journal-title":"Nucl Med Commun"},{"key":"1028_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16030667","author":"N Andryszak","year":"2024","unstructured":"Andryszak N, \u015awiniuch D, W\u00f3jcik E, Ramlau R, Rucha\u0142a M, Czepczy\u0144ski R. Head-to-Head Comparison of [18F]PSMA-1007 and [18F]FDG PET\/CT in Patients with Triple-Negative Breast Cancer. Cancers (Basel). 2024. https:\/\/doi.org\/10.3390\/cancers16030667.","journal-title":"Cancers (Basel)"},{"key":"1028_CR15","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1200\/JCO.2023.41.16_suppl.1025","volume":"41","author":"G Nader Marta","year":"2023","unstructured":"Nader Marta G, Wimana Z, Taraji L, Critchi G, Aftimos P, Piccart-Gebhart M, Flamen P, Gebhart G. Prostate-specific membrane antigen (PSMA) expression in patients with metastatic triple negative breast cancer: Initial results of the PRISMA study. J Clin Oncol. 2023;41:1025\u20131025.","journal-title":"J Clin Oncol"},{"key":"1028_CR16","doi-asserted-by":"publisher","DOI":"10.1097\/MNM.0000000000001820","author":"RV Parghane","year":"2024","unstructured":"Parghane RV, Suralkar T, Nikam D, Basu S. Evaluation of prostate-specific membrane antigen expression in locally advanced or metastatic breast carcinoma with 68 Ga-PSMA-11 positron-emission tomography\/computed tomography imaging for potential theranostics. Nucl Med Commun. 2024. https:\/\/doi.org\/10.1097\/MNM.0000000000001820.","journal-title":"Nucl Med Commun"},{"key":"1028_CR17","doi-asserted-by":"crossref","unstructured":"Annual Congress of the European Association of Nuclear, Medicine. October 4\u20138, 2025 | Barcelona, Spain. EANM Innovation. 2025;1(Supplement):49.","DOI":"10.1016\/S3051-2913(25)00004-7"},{"key":"1028_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-024-01190-7","author":"J Heilinger","year":"2025","unstructured":"Heilinger J, Roth KS, Weis H, Fink A, Weindler J, Dietlein F, Krapf P, Schom\u00e4cker K, Neumaier B, Dietlein M, Drzezga A, Kobe C. Do you know your PSMA-tracer? Variability in the biodistribution of different PSMA ligands and its potential impact on defining PSMA-positivity prior to PSMA-targeted therapy. EJNMMI Res. 2025. https:\/\/doi.org\/10.1186\/s13550-024-01190-7.","journal-title":"EJNMMI Res"},{"key":"1028_CR19","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.222505","author":"BHE Jansen","year":"2019","unstructured":"Jansen BHE, Kramer GM, Cysouw MCF, Yaqub MM, de Keizer B, Lavalaye J, Booij J, Vargas HA, Morris MJ, Vis AN, van Moorselaar RJA, Hoekstra OS, Boellaard R, Oprea-Lager DE. Healthy Tissue Uptake of 68Ga-Prostate-Specific Membrane Antigen, 18F-DCFPyL, 18F-Fluoromethylcholine, and 18F-Dihydrotestosterone. J Nucl Med. 2019. https:\/\/doi.org\/10.2967\/jnumed.118.222505.","journal-title":"J Nucl Med"},{"key":"1028_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15153878","author":"D Groener","year":"2023","unstructured":"Groener D, Wichert J, Adams M, Mader N, Klimek K, Nguyen Ngoc C, Baumgarten J, Happel C, Mandel P, Chun FKH, Tselis N, Gr\u00fcnwald F, Sabet A. Impact of [177Lu]Lu-PSMA-617 Radioligand Therapy on Reference Organ Uptake Assessed by [68Ga]Ga-PSMA-11-PET\/CT. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15153878.","journal-title":"Cancers (Basel)"},{"key":"1028_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00237-3","author":"M Hofman","year":"2021","unstructured":"Hofman M, Emmett L, Sandhu S, Iravani A, Joshua A, Goh J, Pattison D, Tan T, Kirkwood I, Ng S, Francis R, Gedye C, Rutherford NK, Weickhardt A, Scott A, Lee S, Kwan E, Azad A, Ramdave S, Redfern A, Macdonald W, Guminski A, Hsiao E, Chua W, Lin P, Zhang A, McJannett M, Stockler M, Violet J, Williams S, Martin A, Davis I. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021. https:\/\/doi.org\/10.1016\/S0140-6736(21)00237-3.","journal-title":"Lancet"},{"key":"1028_CR22","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.19049","author":"FC Gaertner","year":"2017","unstructured":"Gaertner FC, Halabi K, Ahmadzadehfar H, K\u00fcrpig S, Eppard E, Kotsikopoulos C, Liakos N, Bundschuh RA, Strunk H, Essler M. Uptake of PSMA-ligands in normal tissues is dependent on tumor load in patients with prostate cancer. Oncotarget. 2017. https:\/\/doi.org\/10.18632\/oncotarget.19049.","journal-title":"Oncotarget"},{"issue":"7","key":"1028_CR23","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.2967\/jnumed.117.207316","volume":"59","author":"M Wondergem","year":"2018","unstructured":"Wondergem M, van der Zant FM, Vlottes PW, Knol RJJ. Effects of Fasting on 18F-DCFPyL Uptake in Prostate Cancer Lesions and Tissues with Known High Physiologic Uptake. J Nucl Med. 2018;59(7):1081\u20134.","journal-title":"J Nucl Med"},{"key":"1028_CR24","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.207316","author":"CE Popescu","year":"2024","unstructured":"Popescu CE, Zhang B, Sartoretti T, et al. Evaluating the biodistribution for [68Ga]Ga-PSMA-11 and [18F]F-PSMA-1007 PET\/CT with an inter- and intrapatient based analysis. EJNMMI Res. 2024. https:\/\/doi.org\/10.2967\/jnumed.117.207316.","journal-title":"EJNMMI Res"},{"key":"1028_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-021-00845-z","author":"S Hober\u00fcck","year":"2021","unstructured":"Hober\u00fcck S, L\u00f6ck S, Borkowetz A, Sommer U, Winzer R, Z\u00f6phel K, Fedders D, Michler E, Kotzerke J, Kopka K, H\u00f6lscher T, Braune A. Intraindividual comparison of [68Ga]-Ga-PSMA-11 and [18F]-F-PSMA-1007 in prostate cancer patients: a retrospective single-center analysis. EJNMMI Res. 2021. https:\/\/doi.org\/10.1186\/s13550-021-00845-z.","journal-title":"EJNMMI Res"}],"updated-by":[{"DOI":"10.1186\/s40644-026-01071-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000}}],"container-title":["Cancer Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40644-026-01028-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-026-01028-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-026-01028-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T10:27:46Z","timestamp":1782815266000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40644-026-01028-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1028"],"URL":"https:\/\/doi.org\/10.1186\/s40644-026-01028-6","relation":{},"ISSN":["1470-7330"],"issn-type":[{"value":"1470-7330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"assertion":[{"value":"28 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s40644-026-01071-3","URL":"https:\/\/doi.org\/10.1186\/s40644-026-01071-3","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted at the P. Hertsen Moscow Oncology Research Institute \u2013 the branch of the FSBI \u201cNational Medical Research Radiological Centre\u201d of the Ministry of Health of the Russian Federation following the Declaration of Helsinki and was approved by the local ethical committee. Written informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors affirm that human research participants provided informed consent for publication of the images in Figs.\u00a0\n                      \n                      ,\n                      \n                      and\n                      \n                      .","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"71"}}